Our Motivation




The GHIT Fund is the world’s first product development fund for global health R&D. It is built on the strength of contributions from partners in the public, private, and civil sectors.

The GHIT Fund is a groundbreaking funding response to the failure of free-market mechanisms to facilitate R&D of drugs, vaccines, diagnostics and other products needed by the poorest of the poor in developing nations.

Japan and the GHIT Fund are poised to exercise vigorous leadership in the research, development and commercialization of these products.

The establishment of the GHIT Fund, comprised of Japan's government, private companies, and foundations, represents an unprecedented partnership to pioneer the creation of vital products for developing countries. In the past, mechanisms to promote global health R&D have been largely absent in Japan. The creation of the GHIT Fund marks a new Japanese commitment to global health and a turning point for Japan’s international impact and engagement.

The GHIT Fund's potential impact is reflected in the commitment and diversity of its founders. Japan's public sector has worked tirelessly to convey the country's commitment to global health leadership and engagement to the international community. Japan's private sector continues to advance business opportunities in developing nations and newly emerging economies. Finally, the civil sector of the Fund will strengthen coalitions with development partners.

The GHIT Fund has been launched as a platform to empower a win-win-win relationship among these sectors, while harnessing them in a lasting way to address key global health challenges. This paradigm shift in Japan is now fully underway.

The GHIT Fund's goal is to eliminate devastating infectious diseases in developing nations through the promotion and support of R&D partnerships involving Japanese and overseas partners.

The GHIT Fund is confident that through partnerships, the technology and innovative capacity of Japanese pharmaceutical companies, universities, and research institutes will make a catalytic impact on health issues in the developing world.

The GHIT Fund incorporates PDPs, overseas research, and other initiatives through a platform for global health R&D. We firmly believes that the countless seeds of innovation lying dormant in Japan can be cultivated to serve the poorest of the world's poor, just as Japan used innovative technology to power its own national development.


Promotion of Global R&D Partnerships Between Japan and Overseas → Creation of Japanese Innovation → Improvement – People's Health

Advancing Global Health R&D
GHIT Fund grant investments can be awarded to existing or new partnerships between Japanese and Non-Japanese organizations.

Throughout each year, the GHIT Fund announces investment opportunities for R&D of new drugs, vaccines, or diagnostics for infectious diseases that are prevalent in the developing world, including HIV/AIDS, Tuberculosis, Malaria, and other NTDs.
The scope components may vary with each RFP. Please see ‘Apply for Funding’ page for the detail.



Preventable infectious diseases are causing unnecessary death and misery in the developing world, directly threatening the social infrastructure and economic development of many nations.

Health is a fundamental building block of thriving people, communities, and nations. Healthy people can attend school, go to work, and support families. Healthy communities enrich countries and enable sustainable, stable economies. Now, more than ever, the developing world needs investments in the health of its populations.

The GHIT Fund's definition of “investment in health” is the advancement of global health R&D to improve the health of populations in developing countries through life-saving innovative technology.

The GHIT Fund believes that a key priority for Japan’s international contribution in the 21st century is to encourage domestic innovation that creates products serving the poorest of the poor. In this way, Japan, a world leader in science and technology, can leverage its resources to contribute tangibly to global health.